Emerging Vaccines – Epidemiology – Epidemiology – Emerging Vaccines- Mature Markets

Clarivate Epidemiology’s coverage of emerging vaccines comprises epidemiological estimates of eligible populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the eligible population rate per 1,000 persons for each country, as well as annualized counts projected to the national population.

All populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

The full list of the populations that we forecast for emerging vaccines are as follows:

• HBV vaccine-eligible population, pediatrics.
• HBV vaccine-eligible population, adolescents.
• HBV vaccine-eligible population, adults.
• HBV vaccine newly eligible population, pediatrics.
• HBV vaccine newly eligible population, adolescents.
• HBV vaccine newly eligible population, adults.
• HPV vaccine-eligible population, adolescent males.
• HPV vaccine-eligible population, adolescent females.
• HPV vaccine-eligible population, adult males.
• HPV vaccine-eligible population, adult females.
• HPV vaccine newly eligible population, adolescent males.
• HPV vaccine newly eligible population, adolescent females.
• HPV vaccine newly eligible population, adult males.
• HPV vaccine newly eligible population, adult females.
• Influenza vaccine total eligible population.
• Pneumococcal vaccine total eligible population.
• Pneumococcal vaccine newly eligible population.
• Shingles vaccine total eligible population.
• Shingles vaccine newly eligible population.
• Meningococcal ACWY vaccine total eligible population.
• Meningococcal ACWY vaccine newly eligible population.
• Meningococcal B vaccine total eligible population.
• Meningococcal B vaccine newly eligible population.
• RSV vaccine-eligible population, pediatrics.
• RSV vaccine-eligible population, adults.
• RSV vaccine-eligible population, maternal.
• RSV vaccine newly eligible population, pediatrics.
• RSV vaccine newly eligible population, adults.
• RSV vaccine newly eligible population, maternal.

Note: Coverage may vary by country.